Manuel Martínez-Lavín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Manuel Martínez-Lavín has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Laura-Aline Martínez-Martínez
Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
9 shared publicationsAngélica Almanza
Laboratorio de Fisiología Celular, Dirección de Investigaciones Biomédicas en Salud Mental, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
4 shared publicationsFrancisco Mercado
Laboratorio de Fisiología Celular, Dirección de Investigaciones Biomédicas en Salud Mental, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
4 shared publicationsLuis H. Silveira
Natl Inst Cardiol, Rheumatol Dept, Juan Badiano 1, Mexico City 14080, Mexico
3 shared publications- Luis Manuel Amezcua Guerra
Immunology Department, Instituto Nacional de Cardiología Ignacio Chávez , Mexico City , Mexico
3 shared publications - Angelica Vargas
Departamento de Reumatología del Instituto Nacional de Cardiología Ignacio Chávez
2 shared publications
Latest Publications
- 30 July 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (9) , 5941-5944
Fibromyalgia: a real phantom pain?
Fibromyalgia and phantom limb pain have in common the perception of chronic pain and paresthesia located in areas of the body that have no underlying tissue damage. Debate remains over whether the pain in these two conditions originates in the central nervous system (central sensitization) or dorsal root ganglia. This perspective examines current hypotheses on the pathogenesis of fibromyalgia and phantom limb pain, proposing that knowledge sharing on the mechanisms leading to these two conditions may help to better appraise chronic non-nociceptive pain.
- 30 July 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (9) , 5941-5944
Fibromyalgia: a real phantom pain?
Fibromyalgia and phantom limb pain have in common the perception of chronic pain and paresthesia located in areas of the body that have no underlying tissue damage. Debate remains over whether the pain in these two conditions originates in the central nervous system (central sensitization) or dorsal root ganglia. This perspective examines current hypotheses on the pathogenesis of fibromyalgia and phantom limb pain, proposing that knowledge sharing on the mechanisms leading to these two conditions may help to better appraise chronic non-nociceptive pain.
- Open Access
- 4 June 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Glial fibrillary acidic protein in fibromyalgia: its serum levels and antibodies
Background: Fibromyalgia is a stress-related disorder in which dorsal root ganglia (DRG) may play an important pathogenic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy, where each pain-sensing nerve fiber soma is encased and interacts with immune-competent satellite glial cells (SGCs). Patients suffering from fibromyalgia harbor anti-SGCs antibodies; however, the specific SGCs antigen(s) remain unidentified. Glial fibrillary acidic protein (GFAP) is an intermediate filament protein serving as early SGCs activation marker. Different environmental stressors induce GFAP upregulation and structural modifications, including citrullination, potentially rendering it immunogenic. GFAP antibodies are implicated in autoimmune encephalomyelitis. We determine whether the serum of patients with fibromyalgia, collected before the COVID-19 pandemic, overexpresses GFAP and/or harbors antibodies against GFAP. Methods: We studied 47 women with fibromyalgia and 31 healthy women. For GFAP antibody detection, a sensitive ELISA was developed using recombinant human GFAP. A commercial human GFAP ELISA Kit was used to measure GFAP serum levels. Results: Significantly higher serum GFAP antibody optical density (OD) was detected in patients with fibromyalgia (median 0.04, 0.02–0.10 vs. 0.02, 0.01–0.05; p = 0.025). When the control group 99th percentile value (0.127 OD) was used as positive threshold, 9/47 (19%) patients tested positive for anti-GFAP antibodies. Patients with fibromyalgia showed numerically higher GFAP serum levels: (244.0 pg/ml ± 82.5 SD versus 211.4 ± 65.2. p = 0.057). Conclusion: In this proof-of-concept study, patients suffering from fibromyalgia exhibit higher serum anti-GFAP antibodies and numerically augmented circulating GFAP levels. Future mechanistic studies will define GFAP role in the pathogenesis of FM.
- 4 June 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessGlial fibrillary acidic protein in fibromyalgia: its serum levels and antibodies
Background: Fibromyalgia is a stress-related disorder in which dorsal root ganglia (DRG) may play an important pathogenic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy, where each pain-sensing nerve fiber soma is encased and interacts with immune-competent satellite glial cells (SGCs). Patients suffering from fibromyalgia harbor anti-SGCs antibodies; however, the specific SGCs antigen(s) remain unidentified. Glial fibrillary acidic protein (GFAP) is an intermediate filament protein serving as early SGCs activation marker. Different environmental stressors induce GFAP upregulation and structural modifications, including citrullination, potentially rendering it immunogenic. GFAP antibodies are implicated in autoimmune encephalomyelitis. We determine whether the serum of patients with fibromyalgia, collected before the COVID-19 pandemic, overexpresses GFAP and/or harbors antibodies against GFAP. Methods: We studied 47 women with fibromyalgia and 31 healthy women. For GFAP antibody detection, a sensitive ELISA was developed using recombinant human GFAP. A commercial human GFAP ELISA Kit was used to measure GFAP serum levels. Results: Significantly higher serum GFAP antibody optical density (OD) was detected in patients with fibromyalgia (median 0.04, 0.02–0.10 vs. 0.02, 0.01–0.05; p = 0.025). When the control group 99th percentile value (0.127 OD) was used as positive threshold, 9/47 (19%) patients tested positive for anti-GFAP antibodies. Patients with fibromyalgia showed numerically higher GFAP serum levels: (244.0 pg/ml ± 82.5 SD versus 211.4 ± 65.2. p = 0.057). Conclusion: In this proof-of-concept study, patients suffering from fibromyalgia exhibit higher serum anti-GFAP antibodies and numerically augmented circulating GFAP levels. Future mechanistic studies will define GFAP role in the pathogenesis of FM.
- 22 May 2025
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Acute activation of rat dorsal root ganglion neurons and their satellite glial cells by the serum of patients suffering from fibromyalgia
Full Papers; Authors: F. Mercado, A. Almanza, P. Segura-Chama, V. Galindo-Avendaño, L.-A. Martínez-Martínez, M. Martínez-Lavín
- 22 May 2025
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Acute activation of rat dorsal root ganglion neurons and their satellite glial cells by the serum of patients suffering from fibromyalgia
Full Papers; Authors: F. Mercado, A. Almanza, P. Segura-Chama, V. Galindo-Avendaño, L.-A. Martínez-Martínez, M. Martínez-Lavín
- 22 August 2024
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 43 (1) , 1-3
Fibromyalgia: a satellite gliopathy?
- 22 August 2024
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 43 (1) , 1-3
Fibromyalgia: a satellite gliopathy?
- 14 September 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (11) , 3167-3171
Hypothetical framework for post-COVID 19 condition based on a fibromyalgia pathogenetic model
There is a clear clinical overlap between fibromyalgia, myalgic encephalomyelitis, and post-COVID 19 condition. Chronic fatigue, cognitive impairment, and widespread pain characterize these 3 syndromes. A steady line of investigation posits fibromyalgia as stress-evoked sympathetically maintained neuropathic pain syndrome and places dorsal root ganglia dysregulation with the ensuing small fiber neuropathy at the epicenter of fibromyalgia pathogenesis. This article discusses emerging evidence suggesting that similar mechanism may operate in post-COVID 19 condition.
- 14 September 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (11) , 3167-3171
Hypothetical framework for post-COVID 19 condition based on a fibromyalgia pathogenetic model
There is a clear clinical overlap between fibromyalgia, myalgic encephalomyelitis, and post-COVID 19 condition. Chronic fatigue, cognitive impairment, and widespread pain characterize these 3 syndromes. A steady line of investigation posits fibromyalgia as stress-evoked sympathetically maintained neuropathic pain syndrome and places dorsal root ganglia dysregulation with the ensuing small fiber neuropathy at the epicenter of fibromyalgia pathogenesis. This article discusses emerging evidence suggesting that similar mechanism may operate in post-COVID 19 condition.
- 23 March 2023
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 19 (5) , 318
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?
- 23 March 2023
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 19 (5) , 318
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?
- 14 October 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (12) , 3915-3917
Centralized nociplastic pain causing fibromyalgia: an emperor with no cloths?
The leading school of thought views fibromyalgia as a central sensitization syndrome. Nociplastic pain is the recently proposed term to mechanistically explain central sensitization. Accumulating research suggests an alternate explanation; fibromyalgia can be conceptualized as a neuropathic pain syndrome and dorsal root ganglia (not the brain) as the primary fibromyalgia pain source. There is no need to propose nociplastic pain as new chronic pain mechanism.
- 14 October 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (12) , 3915-3917
Centralized nociplastic pain causing fibromyalgia: an emperor with no cloths?
The leading school of thought views fibromyalgia as a central sensitization syndrome. Nociplastic pain is the recently proposed term to mechanistically explain central sensitization. Accumulating research suggests an alternate explanation; fibromyalgia can be conceptualized as a neuropathic pain syndrome and dorsal root ganglia (not the brain) as the primary fibromyalgia pain source. There is no need to propose nociplastic pain as new chronic pain mechanism.
- 9 June 2022
- Published by Elsevier in Autoimmunity Reviews
- Vol. 21 (8) , 103129
Clinical overlap between fibromyalgia and myalgic encephalomyelitis. A systematic review and meta-analysis
- 9 June 2022
- Published by Elsevier in Autoimmunity Reviews
- Vol. 21 (8) , 103129
Clinical overlap between fibromyalgia and myalgic encephalomyelitis. A systematic review and meta-analysis